Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children

Next Previous
Trial Profile

A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Food allergy immunotherapy (Primary)
  • Indications Eosinophilic oesophagitis; Milk hypersensitivity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SMILEE

Most Recent Events

  • 05 Mar 2019 Status changed from active, no longer recruiting to completed.
  • 04 Feb 2019 According to a DBV Technologies media release, abstract related to results from this trial has been published online on the AAAAI meeting website.
  • 04 Feb 2019 According to a DBV Technologies media release, data from this trial will be presented at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; Food Allergy: Advances in Prevention and Treatment in San Francisco, CA, February 22 -25, 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top